Literature DB >> 22132879

Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

A Vossenkämper1, P M K Lutalo, J Spencer.   

Abstract

Systemic lupus erythematosus (SLE) and Sjögren's syndrome are autoimmune disorders which are characterized by a disturbed B cell homeostasis which leads ultimately to dysfunction of various organs. One of the B cell subsets that appear in abnormal numbers is the population of transitional B cells, which is increased in the blood of patients with SLE and Sjögren's syndrome. Transitional B cells are newly formed B cells. In mice, transitional B cells undergo selection checks for unwanted specificity in the bone marrow and the spleen in order to eliminate autoreactive B cells from the circulating naive B cell population. In humans, the exact anatomical compartments and mechanisms of the specificity check-points for transitional B cells remain unclear, but appear to be defective in SLE and Sjögren's syndrome. This review aims to highlight the current understanding of transitional B cells and their defects in the two disorders before and after B cell-targeted therapies.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22132879      PMCID: PMC3248081          DOI: 10.1111/j.1365-2249.2011.04460.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  79 in total

1.  Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells.

Authors:  Laëtitia Le Pottier; Valérie Devauchelle; Alain Fautrel; Capucine Daridon; Alain Saraux; Pierre Youinou; Jacques-Olivier Pers
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

2.  Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment.

Authors:  J M Meijer; J Pijpe; A Vissink; C G M Kallenberg; H Bootsma
Journal:  Ann Rheum Dis       Date:  2009-02       Impact factor: 19.103

3.  Effects of rituximab on resistant SLE disease including lung involvement.

Authors:  J A Reynolds; V Toescu; C S Yee; A Prabu; D Situnayake; C Gordon
Journal:  Lupus       Date:  2009-01       Impact factor: 2.911

Review 4.  Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.

Authors:  Manuel Ramos-Casals; M J Soto; M J Cuadrado; M A Khamashta
Journal:  Lupus       Date:  2009-08       Impact factor: 2.911

Review 5.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

Authors:  Michael P Cancro; David P D'Cruz; Munther A Khamashta
Journal:  J Clin Invest       Date:  2009-05-01       Impact factor: 14.808

6.  Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.

Authors:  D Albert; J Dunham; S Khan; J Stansberry; S Kolasinski; D Tsai; S Pullman-Mooar; F Barnack; C Striebich; R J Looney; E T Luning Prak; R Kimberly; Y Zhang; R Eisenberg
Journal:  Ann Rheum Dis       Date:  2008-02-04       Impact factor: 19.103

Review 7.  Human marginal zone B cells.

Authors:  Jean-Claude Weill; Sandra Weller; Claude-Agnès Reynaud
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

8.  Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.

Authors:  Annett M Jacobi; Weiqing Huang; Tao Wang; William Freimuth; Inaki Sanz; Richard Furie; Meggan Mackay; Cynthia Aranow; Betty Diamond; Anne Davidson
Journal:  Arthritis Rheum       Date:  2010-01

9.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors:  Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal:  Arthritis Rheum       Date:  2010-01

10.  Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.

Authors:  Richard Furie; William Stohl; Ellen M Ginzler; Michael Becker; Nilamadhab Mishra; Winn Chatham; Joan T Merrill; Arthur Weinstein; W Joseph McCune; John Zhong; Wendy Cai; William Freimuth
Journal:  Arthritis Res Ther       Date:  2008-09-11       Impact factor: 5.156

View more
  16 in total

Review 1.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

Review 2.  To B or not to B cells-mediate a healthy start to life.

Authors:  T G Nguyen; C M Ward; J M Morris
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

3.  n-3 PUFAs enhance the frequency of murine B-cell subsets and restore the impairment of antibody production to a T-independent antigen in obesity.

Authors:  Heather Teague; Cassie J Fhaner; Mitchel Harris; David M Duriancik; Gavin E Reid; Saame Raza Shaikh
Journal:  J Lipid Res       Date:  2013-08-28       Impact factor: 5.922

4.  Central role for marginal zone B cells in an animal model of Sjogren's syndrome.

Authors:  Long Shen; Chun Gao; Lakshmanan Suresh; Zhenhua Xian; Nannan Song; Lee D Chaves; Meixing Yu; Julian L Ambrus
Journal:  Clin Immunol       Date:  2016-04-30       Impact factor: 3.969

5.  Prolactin rescues and primes autoreactive B cells directly and indirectly through dendritic cells in B6.Sle3 mice.

Authors:  J Gonzalez; S Saha; E Peeva
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

Review 6.  B-cell selection and the development of autoantibodies.

Authors:  Natalia V Giltiay; Craig P Chappell; Edward A Clark
Journal:  Arthritis Res Ther       Date:  2012-11-02       Impact factor: 5.156

Review 7.  Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation.

Authors:  Andreas Lossius; Jorunn N Johansen; Øivind Torkildsen; Frode Vartdal; Trygve Holmøy
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

8.  Evidence of dynamically dysregulated gene expression pathways in hyperresponsive B cells from African American lupus patients.

Authors:  Igor Dozmorov; Nicolas Dominguez; Andrea L Sestak; Julie M Robertson; John B Harley; Judith A James; Joel M Guthridge
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

9.  Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens.

Authors:  Jose de Salort; Marta Cuenca; Cox Terhorst; Pablo Engel; Xavier Romero
Journal:  Front Immunol       Date:  2013-07-31       Impact factor: 7.561

10.  Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells.

Authors:  Natalia V Giltiay; Craig P Chappell; Xizhang Sun; Nikita Kolhatkar; Thomas H Teal; Alice E Wiedeman; Jinoh Kim; Lena Tanaka; Matthew B Buechler; Jessica A Hamerman; Thereza Imanishi-Kari; Edward A Clark; Keith B Elkon
Journal:  J Exp Med       Date:  2013-10-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.